Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data.

Carter R, Stocken DD, Ghaneh P, Bramhall SR, Olah A, Kelemen D, Bassi C, Friess H, Dervenis C, Spry N, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer (ESPAC).

Int J Cancer. 2009 Jun 15;124(12):2960-5. doi: 10.1002/ijc.24270.

2.

Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.

Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F, Buckels J, Deakin M, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Büchler MW; European Study Group for Pancreatic Cancer.

Ann Surg. 2001 Dec;234(6):758-68.

3.

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials.

Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D, Büchler MW.

Br J Cancer. 2009 Jan 27;100(2):246-50. doi: 10.1038/sj.bjc.6604838. Epub 2009 Jan 6.

4.

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW; European Study Group for Pancreatic Cancer.

JAMA. 2010 Sep 8;304(10):1073-81. doi: 10.1001/jama.2010.1275.

PMID:
20823433
5.

Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.

Chakravarthy A, Abrams RA, Yeo CJ, Korman LT, Donehower RC, Hruban RH, Zahurek ML, Grochow LB, O'Reilly S, Hurwitz H, Jaffee EM, Lillemoe KD, Cameron JL.

Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1089-96.

PMID:
11072167
6.

Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.

Kim ST, Lee J, Park SH, Lee JK, Lee KT, Lee KH, Heo JS, Choi SH, Choi DW, Park YS, Lim HY, Kang WK, Jang KT, Park HC, Lim DH, Park JO.

Am J Clin Oncol. 2012 Oct;35(5):432-8.

PMID:
21606820
7.

Neoadjuvant and adjuvant strategies for pancreatic cancer.

Ghaneh P, Smith R, Tudor-Smith C, Raraty M, Neoptolemos JP.

Eur J Surg Oncol. 2008 Mar;34(3):297-305. Epub 2007 Oct 22. Review.

PMID:
17936564
8.

Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital.

Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, Campbell KA, Wolfgang CL, Asrari F, Donehower R, Hidalgo M, Diaz LA Jr, Yeo C, Cameron JL, Schulick RD, Abrams R.

J Clin Oncol. 2008 Jul 20;26(21):3503-10. doi: 10.1200/JCO.2007.15.8469.

9.

Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer.

Stocken DD, Büchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP; Pancreatic Cancer Meta-analysis Group.

Br J Cancer. 2005 Apr 25;92(8):1372-81.

10.

Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.

Link KH, Leder G, Formentini A, Fortnagel G, Kornmann M, Schatz M, Beger HG.

Gan To Kagaku Ryoho. 1999 Jan;26(1):10-40. Review.

PMID:
9987495
11.
12.
13.

Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement.

Abbott DE, Merkow RP, Cantor SB, Fleming JB, Varadhachary GR, Crane C, Bentrem DJ, Bilimoria KY.

Ann Surg Oncol. 2012 Nov;19(12):3659-67. doi: 10.1245/s10434-012-2610-1. Epub 2012 Sep 11.

PMID:
22965567
14.

Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD, Cameron JL.

Ann Surg. 1997 May;225(5):621-33; discussion 633-6.

15.

Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.

Combs SE, Habermehl D, Kessel KA, Bergmann F, Werner J, Naumann P, Jäger D, Büchler MW, Debus J.

Ann Surg Oncol. 2014 Aug;21(8):2801-7. doi: 10.1245/s10434-014-3607-8. Epub 2014 Jun 11.

PMID:
24916745
16.

Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer.

Chau I, Norman AR, Cunningham D, Iveson T, Hill M, Hickish T, Lofts F, Jodrell D, Webb A, Tait D, Ross PJ, Shellito P, Oates JR.

Eur J Cancer. 2005 Jul;41(11):1551-9.

PMID:
16026692
17.

Adjuvant therapy in pancreatic cancer: historical and current perspectives.

Neoptolemos JP, Cunningham D, Friess H, Bassi C, Stocken DD, Tait DM, Dunn JA, Dervenis C, Lacaine F, Hickey H, Raraty MG, Ghaneh P, Büchler MW.

Ann Oncol. 2003 May;14(5):675-92. Review.

PMID:
12702520
18.

Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).

Neoptolemos JP, Baker P, Beger H, Link K, Pederzoli P, Bassi C, Dervenis C, Friess H, Büchler M.

Int J Pancreatol. 1997 Apr;21(2):97-104.

PMID:
9209950
19.

Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?

Chen KT, Devarajan K, Milestone BN, Cooper HS, Denlinger C, Cohen SJ, Meyer JE, Hoffman JP.

Ann Surg Oncol. 2014 Feb;21(2):662-9. doi: 10.1245/s10434-013-3396-5. Epub 2013 Nov 26.

PMID:
24276638
20.

Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.

Morak MJ, van der Gaast A, Incrocci L, van Dekken H, Hermans JJ, Jeekel J, Hop WC, Kazemier G, van Eijck CH.

Ann Surg. 2008 Dec;248(6):1031-41. doi: 10.1097/SLA.0b013e318190c53e.

PMID:
19092348

Supplemental Content

Support Center